Artificial Intelligence in Screening and Early Detection of Prostate Cancer.
Authors
Affiliations (3)
Affiliations (3)
- USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, USA; Artificial Intelligence Center at USC Urology, University of Southern California, Los Angeles, USA.
- Department of Translational Medicine, Diagnostic Radiology, Lund University, Malmö, Sweden; Department of Radiology, Helsingborg Hospital, Helsingborg, Sweden.
- Department of Urology, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Urological Cancers, Lund University, Malmö, Sweden. Electronic address: [email protected].
Abstract
Artificial intelligence (AI) is transforming prostate cancer screening and early detection through the integration of clinical-risk calculators, magnetic resonance imaging (MRI), digital pathology, genomics, biomarkers, and liquid biopsies. AI-enhanced risk models may improve biopsy decisions, while AI-assisted MRI interpretation can increase the detection of clinically significant disease and reduce false positives, unnecessary biopsies, and overdiagnosis. Digital pathology algorithms may support more reproducible tumor identification, Gleason grading, and prognostic stratification. Genomic risk scores, kallikrein-based tests, and emerging circulating biomarkers further enable precision screening by identifying men at elevated risk and refining the selection for imaging or biopsy. However, most available systems address isolated components of the diagnostic pathway, and evidence from prospective, real-world screening populations remains limited. Clinical implementation therefore requires external validation, screening-specific calibration, implemented reference standards, and workflow integration. Ultimately, multimodal AI may enable a "virtual biopsy" that combines imaging, molecular, pathological, and clinical data to deliver personalized, noninvasive prostate cancer assessment.